Gilteritinib As Post-Transplant Maintenance for AML with Internal Tandem Duplication Mutation of FLT3.
Mark J. Levis,Mehdi Hamadani,Brent Logan,Richard J. Jones,Anurag K. Singh,Mark Litzow,John R. Wingard,Esperanza B. Papadopoulos,Alexander E. Perl,Robert J. Soiffer,Celalettin Ustun,Masumi Ueda Oshima,Geoffrey L. Uy,Edmund K. Waller,Sumithra Vasu,Melhem Solh,Asmita Mishra,Lori Muffly,Hee-Je Kim,Jan-Henrik Mikesch,Yuho Najima,Masahiro Onozawa,Kirsty Thomson,Arnon Nagler,Andrew H. Wei,Guido Marcucci,Nancy L. Geller,Nahla Hasabou,David Delgado,Matt Rosales,Jason Hill,Stanley C. Gill,Rishita Nuthethi, Denise King, Heather Wittsack,Adam Mendizabal,Steven M. Devine,Mary M. Horowitz,Yi-Bin Chen JOURNAL OF CLINICAL ONCOLOGY（2024）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper